We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -15.91 | -2.10% | 740.00 | 745.00 | 730.34 | 743.10 | 4,593,881 | 01:00:00 |
From May 2019 to May 2024
By Matt Grossman
Eli Lilly & Co. and Incyte Corp. said Monday that their trial of a treatment for Covid-19 successfully reduced the amount of time it took for patients to recover.
In the trial of more than 1,000 patients, people hospitalized with Covid-19 were given a 4-milligram dose of baricitinib plus remdesivir. The treatment led to recoveries that were about one day quicker, at the median, than those of patients who only got remdesivir.
The National Institute of Allergy and Infectious Diseases, which sponsored the trial, will publish the results in a journal, the companies said.
Eli Lilly said it will discuss an emergency-use authorization for 4-mg doses of baricitinib with the Food and Drug Administration. In the U.S., the drug is already approved in 2-mg doses to tread rheumatoid arthritis. Eli Lilly said the supply of the drug for patients with that disease will remain adequate.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 14, 2020 06:57 ET (10:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
